16 July 2019

The number of people diagnosed with B-cell non-Hodgkin’s lymphoma (NHL) in seven industrialised countries is likely to rise by almost 2% annually up to 2027, according to a new analysis.

A report by GlobalData, “B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027”, reveals that the numbers of new cases in USA, France, Germany, Italy, Spain, the UK and Japan are likely to grow from about 154,000 new cases in 2017 to 183,000 cases in 2027 – an annual increase of 1.87%.

GlobalData says this is partly attributed to the moderately rising trend in incidence, combined with underlying demographic changes. Its report says that in the seven countries, diffuse large B-cell lymphoma (DLBCL) was the most common subtype of B-cell NHL, followed by follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

Bishal Bhandari, epidemiologist at GlobalData, said: “GlobalData’s research shows that DLBCL is the most common subtype of B-cell NHL. This is important as it is the more aggressive form of cancer with poor prognosis and the risk of mortality from DLBCL will increase in the elderly population with other co-existing diseases and conditions; making it an important patient population to focus on.”

The majority of diagnosed incident cases of DLBCL were in stage IV and the fewest were in stage III in 2017 in the countries analysed, he added.

“It is worrying that most cases of DLBCL were diagnosed in the advanced stages as survival will be poor and patients would have required aggressive therapy to get the cancer under control,” he said.

“There is a need for diagnostic tools to detect aggressive cancer such as DLBCL at earlier stages and treatment priorities should also be aligned to address the aggressive form of cancer.”

Source: GlobalData - “B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027”


Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/